JP2023549075A5 - - Google Patents

Info

Publication number
JP2023549075A5
JP2023549075A5 JP2023526226A JP2023526226A JP2023549075A5 JP 2023549075 A5 JP2023549075 A5 JP 2023549075A5 JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023549075 A5 JP2023549075 A5 JP 2023549075A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
nmosd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023526226A
Other languages
English (en)
Japanese (ja)
Other versions
JP7900888B2 (ja
JP2023549075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057443 external-priority patent/WO2022094334A1/en
Publication of JP2023549075A publication Critical patent/JP2023549075A/ja
Publication of JP2023549075A5 publication Critical patent/JP2023549075A5/ja
Priority to JP2026066113A priority Critical patent/JP2026120679A/ja
Application granted granted Critical
Publication of JP7900888B2 publication Critical patent/JP7900888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023526226A 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 Active JP7900888B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026066113A JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026066113A Division JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Publications (3)

Publication Number Publication Date
JP2023549075A JP2023549075A (ja) 2023-11-22
JP2023549075A5 true JP2023549075A5 (cg-RX-API-DMAC10.html) 2024-11-07
JP7900888B2 JP7900888B2 (ja) 2026-08-05

Family

ID=81384348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023526226A Active JP7900888B2 (ja) 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
JP2026066113A Pending JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026066113A Pending JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Country Status (10)

Country Link
US (1) US20230287114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4237447A4 (cg-RX-API-DMAC10.html)
JP (2) JP7900888B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230097118A (cg-RX-API-DMAC10.html)
AU (1) AU2021368769A1 (cg-RX-API-DMAC10.html)
CA (1) CA3197022A1 (cg-RX-API-DMAC10.html)
IL (1) IL302294A (cg-RX-API-DMAC10.html)
MX (1) MX2023004794A (cg-RX-API-DMAC10.html)
TW (1) TW202233676A (cg-RX-API-DMAC10.html)
WO (1) WO2022094334A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Similar Documents

Publication Publication Date Title
Foster et al. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study
US8835487B2 (en) Method of treating multiple sclerosis
JP2022553329A5 (cg-RX-API-DMAC10.html)
JP2022529743A5 (cg-RX-API-DMAC10.html)
WO2021041773A1 (en) Methods for the treatment of thyroid eye disease
WO2022187510A1 (en) Methods for the treatment of thyroid eye disease
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
TW202227131A (zh) 帕金森氏症之治療
Kaur et al. Optic neuritis and the neuro‐ophthalmology of multiple sclerosis
Sokmen et al. A case with Neurofascin-155 IgG antibody-associated combined central and peripheral demyelination: Successfully treated with anti-CD20 monoclonal antibody
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
Bhat et al. Intravenous daclizumab for recalcitrant ocular inflammatory disease
US20230406928A1 (en) Methods of treating neuromyelitis optica spectrum disorder
JP2024540294A5 (cg-RX-API-DMAC10.html)
Bromfield et al. Phenytoin withdrawal and seizure frequency
TW202233676A (zh) 使用抗ｃｄ１９抗體治療自體免疫性疾病
Kes et al. Therapeutic Plasma Exchange in the Neurologic Intensive Care Setting: Recommendation for Clinical Practice
Harris et al. Acute demyelinating disorders of the central nervous system
Ha et al. Clinical preoperative and postoperative symptoms of exotropia
KR101226605B1 (ko) 질병의 치료
AU2022230300A1 (en) Treatment and/or reduction of occurrence of migraine
Mehndiratta et al. Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy
Singh et al. Targeted steroid delivery for myelin oligodendrocyte glycoprotein antibody-associated rare optic neuritis: Clinical outcome and review literature
HK40087593A (en) Methods of treating neuromyelitis optica spectrum disorder
TW202317181A (zh) 治療視神經脊髓炎譜系障礙之方法